Clinical Trials
- Gastrointestinal Oncology
- Clinical Trials
Thank you for your interest in GI clinical trials at UCSF.
Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.
Please see the links below for current open trials at UC San Francisco.
COLORECTAL
ANAL
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
Contact: Rachel Silverstein (415) 353-7443:Rachel.Silverstein@ucsf.edu
METASTATIC
CC#16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)
Contact: Kate Mohan (415) 476-3816:Katherine.Mohan@ucsf.edu
CC#16706: A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MDG009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3
Contact: Luat Le (415) 502-8075: Luat.Le@ucsf.edu
CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Contact: Hannah McKenna (415) 353-8449:Hannah.McKenna@ucsf.edu
CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Contact: Julia Whitman (415) 353-7683:Julia.Whitman@ucsf.edu
CC#174528: A Study of Nivolumab in Combination With Trametinib or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers
Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
CC#174528: A Study of Nivolumab in Combination With Trametinib or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers
Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
CC#177015: A Phase 1A/1B Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients with Locally Advanced or Metastatic Tumors
Contact: Sophia Bylsma (415) 502-4760:Sophia.Bylsma@ucsf.edu
NEOADJUVANT RECTAL
Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu
EARLY PHASE
AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Erika Zigman (415) 514-6248:Erika.Zigman@ucsf.edu
CC#16954: Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors.
Contact: Erika Zigman (415) 514-6248:Erika.Zigman@ucsf.edu
CC#169516 : A Phase I/II, Multicenter, Open-Label Study of MAK683 in Adult Patients With Advanced Malignancies
Contact: Ro Rahimi (415) 885-3728:Roshun.Rahimi@ucsf.edu
CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Contact: Hannah McKenna (415) 353-8449:Hannah.McKenna@ucsf.edu
CC#169519: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (only SCLC and TNBC)
Contact: Meg Hanley (415) 353-3642:Margaret.Hanley@ucsf.edu
CC#169521: Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair (Note: restricted to patients with defects in the following molecules: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)
Contact: Ro Rahimi (415) 885-3728:Roshun.Rahimi@ucsf.edu
CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Contact: Melissa Lopez (415) 885-3728:Melissa.Lopez@ucsf.edu
CC#17953: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors:
Contact: Lucas Rohrer (415) 353-3642:Lucas.Rohrer@ucsf.edu
CC#17955: A Phase 1, Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and c- Met Dysregulation
Contact: Melissa Lopez (415) 885-3728:Melissa.Lopez@ucsf.edu
CC#18952: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Contact: Claire Hooker (415) 353-7084:Claire.Hooker@ucsf.edu
CC#18955: A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Contact: Lucas Rohrer (415) 353-3642:Lucas.Rohrer@ucsf.edu
CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies
Contact: Hannah McKenna (415) 353-8449:Hannah.McKenna@ucsf.edu
CC#18959: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Contact: Hannah McKenna (415) 353-8449:Hannah.McKenna@ucsf.edu
CC#189510: Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies
Contact: Lucas Rohrer (415) 353-3642:Lucas.Rohrer@ucsf.edu
CC#189511: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
Contact: Melissa Lopez (415) 885-3728:Melissa.Lopez@ucsf.edu
GASTRO ESOPHAGEAL
CC#16459: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Contact: Hannah McKenna (415) 353-8449:Hannah.McKenna@ucsf.edu
CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Christopher Wong (415) 476-1044:Christopher.Wong@ucsf.edu
CC#18453: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-Line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Contact: Mikaela Esquivel (415) 353-7145:Mikaela.Esquivel@ucsf.edu
CC#18955: A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Contact: Claire Hooker (415) 353-7084:Claire.Hooker@ucsf.edu
HEPATOCELLULAR and BILIARY TRACT
CC#15452: A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant To Platinum-Based Chemotherapy
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
CC#154524: A Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers
Contact: Brenna Sheldon (415) 476-5442:Brenna.Sheldon@ucsf.edu
CC#16451: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Contact: Trang Nguyen (415) 353-9544: TrangX.Nguyen@ucsf.edu
CC#164514: Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization in Hepatocellular Carcinoma
Contact: Melanie Regan (415) 514-8995:Melanie.Regan@ucsf.edu
CC#17451: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
Contact: Lillian Jahan (415) 502-4174: Lillian.Jahan@ucsf.edu
CC#17457: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities
Contact: Lillian Jahan (415) 502-4174: Lillian.Jahan@ucsf.edu
CC#174523: A Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
CC#174532: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
CC#177015: A Phase 1A/1B Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients with Locally Advanced or Metastatic Tumors
Contact: Sophia Bylsma (415) 502-4760:Sophia.Bylsma@ucsf.edu
IMMUNOTHERAPY
CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)
Contact: Kate Mohan (415) 476-3816:Katherine.Mohan@ucsf.edu
CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Christopher Wong (415) 476-1044:Christopher.Wong@ucsf.edu
CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy For Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases
Contact: Luat Le (415) 502-8075: Luat.Le@ucsf.edu
CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Contact: Christopher Wong (415) 476-1044:Christopher.Wong@ucsf.edu
CC#177015: A Phase 1A/1B Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients with Locally Advanced or Metastatic Tumors
Contact: Sophia Bylsma (415) 502-4760:Sophia.Bylsma@ucsf.edu
NEUROENDOCRINE TUMORS
CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Contact: Lila Modarresi (415) 885-3724:Lila.Modarresi@ucsf.edu
CC#16955: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors
Contact: Lucas Rohrer (415) 353-3642:Lucas.Rohrer@ucsf.edu
CC#17459: Phase II Randomized Embolization Trial for Neuroendocrine Tumor Metastases To The Liver (RETNET)
Contact: Melanie Regan (415) 514-8995:Melanie.Regan@ucsf.edu
CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy For Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases
Contact: Luat Le (415) 502-8075: Luat.Le@ucsf.edu
A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression On Everolimus (CABINET)
Contact: Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu
NON-THERAPEUTIC
CC#164519: Circulating Tumor Derived Cell-Free DNA as a Novel Biomarker to Predict Recurrence of Colorectal Cancer
Contact; Brandon Shih (415) 885-7740: Brandon.Shih@ucsf.edu
CC#174525: Self-Monitoring and Reminder Texts for Physical Activity After Cancer II (Smart Pace II)
Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
CC#174527: GO – Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer
Contact: Julia Whitman (415) 353-7683:Julia.Whitman@ucsf.edu
PANCREATIC
CC#16706: A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MDG009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3
Contact: Luat Le (415) 502-8075: Luat.Le@ucsf.edu
CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Contact: Hannah McKenna (415) 353-8449:Hannah.McKenna@ucsf.edu
CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Contact: Christopher Wong (415) 476-1044:Christopher.Wong@ucsf.edu
CC#174512: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer)
Contact: Shohei Burns (415) 514-6258:Shohei.Burns@ucsf.edu
**************************************************
**TO BE OPENED WITHIN 3 MONTHS**
CC#18454: Predictors of Response to Systemic Therapy In Pancreatic Cancer
Contact: Malori Mindo (415) 502-6313:Malori.Mindo@ucsf.edu
CC#184517: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Contact: Kelly Bauer (415) 514-5633: Kelly.Bauer@ucsf.edu
CC#184519: Cell Free DNA and Imaging in Advanced Gastrointestinal Cancers
Contact: Malori Mindo (415) 502-6313:Malori.Mindo@ucsf.edu
CC#19453: A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy
Contact: Kelly Bauer (415) 514-5633: Kelly.Bauer@ucsf.edu
CC#187011: A Phase 1/1b Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma
Contact: Andrew Chon (415) 476-2351;Andrew.Chon@ucsf.edu
CC#187015: A Phase II Study of Preoperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Andrew Chon (415) 476-2351; Andrew.Chon@ucsf.edu
CC#17956: A Phase 1 Study of LY3200882 in Patients with Solid Tumor (SIV is scheduled for 3/12, looking to open by end of March)
Contact: Meg Hanley (415) 353-3642: Margaret.Hanley@ucsf.edu
CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma *Sponsor Announced Drug Reformulation –1st Patient now expected April 2019*
Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu
CC#186514: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors RMC-4630 is a potent, selective, and orally bioavailable SHP2 allosteric inhibitor that is being developed for patients with tumors harboring certain activating mutations or other genotypic aberrations in the RAS–MAPK pathway, including upstream mutations in RTKs.
Contact: Katie Comerford (415) 353-9535 Kathleen.Comerford@ucsf.edu
CC#189515: A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation
Contact: Phu Lam (415) 353-8337: Phu.Lam@ucsf.edu
CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.
Contact: Phu Lam (415) 353-8337: Phu.Lam@ucsf.edu
CC#189519: An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and
Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors
Contact: Katie Comerford (415) 353-9535: Kathleen.Comerford@ucsf.edu
CC#19952: A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3
Contact: Katie Comerford (415) 353-9535: Kathleen.Comerford@ucsf.edu
CC#19954: A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of AO-176
Contact: Katie Comerford (415) 353-9535:Kathleen.Comerford@ucsf.edu
CC#19955: Protocol 101-18101 – An Open-Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Contact: Katie Comerford (415) 353-9535:Kathleen.Comerford@ucsf.edu
For information on Early Phase clinical trials not listed please contact:
Kamran Abri Lavasani (415) 514-6245: Kamran.AbriLavasani@ucsf.edu
For information on Immunotherapy trials not listed please contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu